FARMINGDALE, N.Y., April 29, 2015 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced it has entered into an exclusive three-year national supply contract with MedAssets, one of the nation's largest third-party providers of supply chain management and procurement capabilities. MedAssets manages approximately $59 billion in annual supply spend on behalf of its clients.

"With MedAssets serving four out of five U.S. hospitals and approximately 123,000 non-acute healthcare providers, we are very excited to enter into this exclusive agreement for our BoneScalpel and SonicOne surgical technologies.  This is simply a great opportunity for many more healthcare facilities and their patients to ultimately benefit from our technology," commented Michael A McManus, President and CEO of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/misonix-announces-exclusive-supply-agreement-with-medassets-for-bonescalpel-and-sonicone-or-300074343.html

SOURCE Misonix, Inc.